Sort by
Refine Your Search
-
Category
-
Country
-
Employer
- University of Cambridge;
- Autonomous University of Madrid (Universidad Autónoma de Madrid)
- Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
- IBIMA Plataforma BIONAND
- Johannes Gutenberg University Mainz •
- Monash University
- Purdue University
- SciLifeLab
- The Ohio State University
- The University of Chicago
- University of Basel
- University of Birmingham
- University of Gdansk
- University of Mainz
- Université Paris Cité
- 6 more »
- « less
-
Field
-
discrimination of tumour metabolites. This fundamental research aims to pave the way for universal MR1-based anti-cancer immunotherapies. The successful candidate gains hands-on expertise in recombinant protein
-
dependencies in cell and primary patient models. Jointly supervised by Dr. Tianyi Zhang and Professors Guy Pratt and Sarah Dimeloe who will provide supervision in genome biology, immunology and immunotherapy and
-
Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer | Spain | 7 days ago
hepatic oncology, Josep M. Llovet Project: Characterization and Impact of Intratumoral and Gut Microbiome on Immunotherapy Response in Hepatocellular Carcinoma Desirable criteria: Laboratory Experience
-
their commercialization and implementation into clinical practice. ICCVS works on a range of national and international research projects concentrating on cancer biology and novel approaches to immunotherapies. The focus
-
/halim-group/ The immune system is capable of detecting cancer, which forms the basis of immunotherapy. While immunotherapy has revolutionised cancer treatment in recent years, it remains unclear how
-
benefit while sparing those unlikely to respond from their toxicities remains a major challenge. Many modern therapies, like immunotherapy and ADCs, rely on tissue architecture to be effective
-
the guidance of Dr. Acharya, the Researcher 2 will conduct specialized research aimed at identifying novel therapeutics that can synergize with existing immunotherapy modalities. The Researcher 2 will
-
-Oncology by leading projects aimed at developing therapeutic strategies that enhance innate immunity against cancers that are refractory to immunotherapy. The appointees will be expected to build internal
-
immunotherapy. Possible project elements include: Artificial cells that process cytokine signals or re-establish tissue homeostasis Synthetic signaling hubs for tumor-microenvironment models Reporter cell assays
-
multimodal algorithm of epigenetic blood predictors of the clinical benefit of SBRT in immunotherapy-resistant tumors Research Line: IBIMA-BE-17 CLINICAL, MOLECULAR, AND TECHNOLOGICAL RESEARCH IN RADIATION